Radiofrequency capacitive hyperthermia combined with irradiation or chemotherapy for patients with invasive bladder cancers

To assess the immediate therapeutic clinical efficacy and long-term outcome, hyperthermia in combination with irradiation or chemotherapeutic agent was used in 46 patients with invasive bladder cancer. Radiohyperthermia (RH) was employed in 19 cases and chemohyperthermia (CH) in 27 cases. Complete r...

Full description

Saved in:
Bibliographic Details
Published inInternational urology and nephrology Vol. 27; no. 6; p. 735
Main Authors Uchibayashi, T, Yamamoto, H, Kunimi, K, Koshida, K, Nakajima, K
Format Journal Article
LanguageEnglish
Published Netherlands 01.11.1995
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Hyperthermia, Induced
Male
Middle Aged
Neoplasm Invasiveness
Prognosis
Radiotherapy, Adjuvant
Survival Rate
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - therapy
Online AccessGet more information

Cover

More Information
Summary:To assess the immediate therapeutic clinical efficacy and long-term outcome, hyperthermia in combination with irradiation or chemotherapeutic agent was used in 46 patients with invasive bladder cancer. Radiohyperthermia (RH) was employed in 19 cases and chemohyperthermia (CH) in 27 cases. Complete response (CR) was obtained in 5 and partial response (PR) in 15 of the 46 cases. One-year survival rates by the Kaplan-Meier method were 65.0% in the CR/PR group and 46.2% in the no change (NC)/progressive disease (PD) group. Five-year survival rates were 43.8% and 18.3%, showing no difference in survival rate between the CR/PR group and the NC/PD group The overall median survival period for the CR/PR group without metastasis was 61.6 months compared to 32.3 months for the NC/PD group without metastasis (P < 0.05).
ISSN:0301-1623
DOI:10.1007/BF02552139